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PMH11
DOES THE SHORT-TERM ADMINISTRATION OF
A BENZODIAZEPINE IMPROVE COMPLIANCE
WITH ANTIDEPRESSANT THERAPY?
Mark TL1, Kevin M2,Torigoe Y2
1Medstat, Washington, DC, USA; 2Pharmacia Corporation,
Peapack, NJ, USA
OBJECTIVES: Several recent clinical guidelines recom-
mend using benzodiazepines as a bridging agent with
antidepressants. Studies show that benzodiazepines may
reduce the initial side effects associated with antidepres-
sants such as jitteriness and therefore increase compli-
ance. The goal of this study is to examine whether
compliance or persistence is higher in patients taking ben-
zodiazepines and antidepressants as compared to those
taking antidepressants alone. METHODS: Data came
from the Medstat Marketscan insurance claims database
which includes claims from several million persons with
private health insurance. Individuals were included if they
met the following inclusion criteria: 18 years of age or
older on January 1, 1999; prescribed an antidepressant
within a 2 year time frame (1999 to 2000); enrolled for
at least 60 days after the ﬁrst date of the ﬁrst antidepres-
sant prescription, and not prescribed an antidepressant
within a baseline period of 60 days. Individuals were
deﬁned as benzodiazepine and antidepressant users if they
had ﬁlled a prescription for benzodiazepines in the 30
days prior or 30 days after the prescription for the anti-
depressants. Individuals were considered as having per-
sistence if they either: had at least 2 prescriptions for an
antidepressant occurring within 60 days of each other, or
had one antidepressant prescription with a greater than a
30-day supply. Multivariate logistic regression analysis
was estimated where persistence was the dependent vari-
able and the controls included age, gender, and diagnosis.
RESULTS: Persons taking benzodiazepines in conjuction
with antidepressants had 1.11 times the odds of having
persistence versus persons taking an antidepressant as a
monotherapy. CONCLUSIONS: Physicians should con-
sider using benzodiazepines to improve compliance with
antidepressant therapy.
PMH12
ASSESSING THE RELATIONSHIP OF
GENERALIZED ANXIETY DISORDER AND
PEPTIC ULCER DISEASE
Kassulke JP, Marks AS, Patel H
Caremark, Inc, Northbrook, IL, USA
OBJECTIVES: To identify through retrospective phar-
macy claims analysis the relationship between generalized
anxiety disorder (GAD) and peptic ulcer disease (PUD).
METHODS: A total of 3.7 million continuously eligible
participants (age 18–64) in Caremark’s pharmacy claims
database were retrospectively analyzed for treatment of
GAD and/or PUD from January 2001 through December
2001. Participants were categorized as having either GAD
or PUD when a pharmacy-targeting algorithm was trig-
gered for respective disease states during the time period.
Multivariate logistic regression analysis was used to
determine the relationship between GAD and PUD, con-
trolling for differences in age, gender and income. Multi-
variate logistic regression analysis was also used to
determine the relationship between GAD and the pres-
ence of chronic conditions, excluding allergic rhinitis.
RESULTS: Participants being treated for GAD were asso-
ciated with an increased risk of being treated for PUD
(OR: 2.18, 95% CI: 2.05–2.33; p < 0.0001). Participants
suffering from chronic conditions were associated with an
increased risk of being treated for GAD (OR: 1.99, 95%
CI: 1.98–2.00; p < 0.0001). Participants being treated for
two or more chronic disease states were associated with
an increased risk of being treated for GAD; 2 chronic con-
ditions (N = 437,637, OR: 2.49, 95% CI: 2.46–2.51; p
< 0.0001); 3 chronic conditions (N = 126,624,odds ratio
4.06, 95% CI = 4.00–4.13, p < 0.0001); 4 or more
chronic conditions (N = 34,411, OR: 6.30, 95% CI:
6.14–6.48, p < 0.0001). CONCLUSION: The relation-
ship between GAD and PUD is consistent with previously
published ﬁndings (Goodwin et al. 2002). However, addi-
tional analysis presented here shows that the presence of
two or more chronic condition increases the risk for
GAD. Therefore, the correlation initially identiﬁed
between GAD and PUD may be indicative of the presence
of an underlying chronic condition causing an anxiety
disorder. This evidence suggests that GAD should be con-
sidered as a comorbidity of chronic disease and should be
incorporated into management strategies.
PMH13
POLYPHARMACOTHERAPY OF INPATIENTS
WITH SCHIZOPHRENIA
Zhao Z1, Wang PF2, Gutierrez B2, Gaylord B2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Premier, Inc,
Charlotte, NC, USA
OBJECTIVE: To examine recent pharmacologic treat-
ment patterns for hospitalized schizophrenia patients.
METHODS: Premier’s PerspectiveTM database, the
largest U.S. hospital drug utilization database, was used
to identify hospitalized schizophrenia patients discharged
between January 1999 and September 2001. Treatment
regimens for ﬁve classes of psychotropics were analyzed.
Regressions examined relationships between polyphar-
macy patterns and diagnoses, illness severity, and patient
and institution characteristics. RESULTS: Of 42,233
patients (55% male, mean age 42 years), 94.9% received
antipsychotics; 74.4% atypicals, most commonly olanza-
pine (46.5%). Mood stabilizers were used by 40.9% 
of patients, antidepressants by 47.6%, anxiolytics by
66.8%, and hypnotics by 23.4%. Only 7.9% of patients
received monotherapy. On average, patients received 3.67
psychotropics; 74.2% received 3 and 27.4% received 5
psychotropics. Most common regimens were antipsy-
chotic and anxiolytic combinations (13.6%); this combi-
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nation plus either antidepressants (12.2%), mood-stabi-
lizers (10.5%), or both (9.9%); and antipsychotics alone
(9.6%). Greater severity, female, paranoid or schizoaf-
fective diagnoses, non-teaching and for-proﬁt hospitals
were associated with increased polypharmacy use.
Patients in public programs (Medicaid/Medicare) received
less atypical antipsychotics but more polypharmacy com-
pared to those in managed care and commercial pro-
grams. Atypical antipsychotic use increased and lithium
use decreased from 1999–2001. CONCLUSIONS:
Polypharmacy is common among hospitalized schizo-
phrenia patients. Patient and institution characteristics
inﬂuenced treatment.
PMH14
CLINICAL PROFILES OF SSRI USERS:
FACTS EXTRACTED FROM HEALTH CARE
CLAIMS DATA
Huang X, Lynn TE, Lutgen J
Ingenix, Eden Prairie, MN, USA
OBJECTIVES: The Clinical Care GroupsTM (CCG) soft-
ware transforms fragmented claims data into episodes of
medical conditions. The results of health care claims data
grouped by CCG indicate that many SSRI claims are not
grouped into a medically related episode. Our objective
is to describe the clinical proﬁles of SSRI users who have
ungrouped SSRI claim(s). METHODS: A random sample
(N = 1,400,000) of individuals was generated for the
study from de-identiﬁed health care claims data of a large
U.S. health plan. Individuals who had been continuously
enrolled in the health plan for the 24-month full period
between April 1, 1999 and March 30, 2001 were eligible
for the study. Those with at least 1 SSRI pharmacy claim
were selected (N = 74,739). An equal number of individ-
uals without SSRI claims were also selected. Medical and
pharmacy claims data were run through CCG version 3.1
and generated the following groups of individuals: Group
A consisting of non-SSRI users; Group B consisting of
individuals with grouped SSRI claims; and Group C con-
sisting of individuals with at least one ungrouped SSRI
claim. RESULTS: The average age in each group was: A—
36, B—42, and C—45. Prevalence of SSRI indicated dis-
orders in each group were: A—54, B—724, and C—56
(cases/1000 members). On average, individuals in group
C had 7 SSRI prescriptions whereas individuals in group
B had 9. The average health care utilization for each
group was: A—$4051, B—$9574, and C—$7920. The
average number of unique providers visited for each
group was: A—9.5, B—16.5, and C—13.4. Of the
grouped SSRI prescriptions, psychiatrists prescribed
25.0% whereas only 7.6% of the ungrouped SSRI were
prescribed by psychiatrists. CONCLUSION: Signiﬁcant
differences exist between individuals with and without
ungrouped SSRI prescriptions and may illuminate the
cause of ungrouped SSRI prescriptions.
PMH15
PREDICTORS OF DURATION OF VISITS AMONG
PATIENTS DIAGNOSED WITH DEPRESSION IN
THE AMBULATORY MEDICAL CARE SETTINGS 
Hou X
University of California, Berkeley, Berkeley, CA, USA
OBJECTIVE: This study was designed to identify predic-
tors of duration of visits among patients diagnosed 
with depression in the ambulatory medical care settings.
METHOD: Data from the 1999 National Ambulatory
Medical Care Survey (NAMCS) were used to identify
patients 10 to 75 years old with a documented diagnosis
of depression (ICD-9-CM = 296.2–296.36; 300.4 or
311). The unweighted sample size was 826. Multivariate
linear regression was used to identify the predictors.
Model variables included patients’ characteristics, treat-
ment patients received, and physicians’ characteristics.
RESULTS: Among the factors predictive of the duration
of visits, signiﬁcant factors include female patients, Med-
icaid patients, capitated payment, seen by other providers
and receipt of psychotherapy. After controlling for other
factors, physicians spend about 2.19 (95% CI: 0.03,4.35)
minutes longer with female patients during the visit than
male patients; physicians spend 8.13 (95% CI: 1.93,
14.32) minutes less with Medicaid patients compared
with patients with private insurance; Physicians spend
8.57 (95% CI: 3.96, 13.18) minutes less with patients in
a capitated visit compared to a non-capitated visit; Estab-
lished patients receive 12.30 (95% CI: 5.30, 19.31)
minutes less with the physician provider compared with
non- established patients; Patients who receive care from
other providers besides a physician such as a physician
assistant, a nurse practitioner, a nurse midwife, a R.N., a
L.P.N., a medical or nursing assistant spend 6.96 minutes
(95% CI: 3.14, 10.77) less with the physician compared
with patients who don’t receive care from other
providers. Patients who receive psychotherapy spend
15.60 (95% CI: 11.04, 20.06) minutes more than patients
who don’t receive psychotherapy. CONCLUSION: Med-
icaid, capitation payment and seen by other providers
were three signiﬁcant and negative predictors of the dura-
tion of the visit. Economic incentives may cause providers
to spend less time with patients or substitute with rela-
tive cheaper health care professionals.
PMH16
PREVALENCE AND TRENDS IN ANTIPSYCHOTIC
POLYPHARMACY AMONG MEDICAID ELIGIBLE
SCHIZOPHRENIA PATIENTS IN CALIFORNIA
AND GEORGIA, 1998–2000
Ganguly R, Miller LS, Martin BC
University of Georgia, Athens, GA, USA
OBJECTIVES: To estimate the prevalence and trends of
antipsychotic polypharmacy, categorize polypharmacy
according to the type of antipsychotic and duration of
use, and contrast polypharmacy usage patterns with pub-
